Best Diabetes Companies in United Kingdom
The 59 best Diabetes companies in United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Apollo Therapeutics.
Ranked by disclosed equity funding and recent momentum, the 59 Diabetes companies tracked in the United Kingdom have pulled in $1.0B in total disclosed funding, with zero unicorns and a funding spread that tells you exactly where the real bets are concentrated. Apollo Therapeutics leads at $372M, followed by Quell at $344M. Those two alone account for the bulk of that pool. The global diabetes market sits at roughly $12.0B in 2025, growing at a 5.92% CAGR, driven by rising prevalence and expanding awareness worldwide, with global players like Novo Nordisk and Eli Lilly setting the commercial ceiling that UK startups are building toward.
Hot themes right now are nutritional and dietary, diabetes meal planning, blood sugar diet, diabetes food choices. Coverage is flat. But funding isn't, and the investor roster here, Europa, Parkwalk, Bristol Private Equity Club, the EIC Fund, and government bodies, signals institutional conviction rather than speculative noise. I'd watch the mid-tier closely: WaveBreak ($60M) and Laverock Therapeutics ($39M) sit in a bracket where neuropathy detection and adjacent diagnostic innovation are gaining real traction. So if you're mapping where UK diabetes capital flows next, the answer is probably in that middle band, not the headline names.
Ranked: Best Diabetes companies in United Kingdom
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Apollo Therapeutics Developer of therapeutic programs based on biological and medical research | $372M | 34 mo ago | 11 | Richard Mason CEO | — | Series C | — | — |
| 2 | Quell Developer of engineered regulatory T cell therapies for immune diseases | $344M | 42 mo ago | 18 | Giovanna Lombardi Co-Founder | TurbopackNode.jsSalesforce+13 | Series B | — | 1 partnership |
| 3 | WaveBreak Developer of small molecule therapeutics for neurological disorders | $60M | 27 mo ago | 51 | Bart Henderson CEO | — | Series A | — | — |
| 4 | Cellnovo Smart device for diabetic management | $48M | 110 mo ago | 92 | — | — | Deadpooled | 90 patents Wearable, smartphone‑controlled insulin and drug infusion pumps with fault‑tolerant cartridge management. | — |
| 5 | Mogrify Developer of regenerative medicine and cell therapies | $48M | 33 mo ago | 45 | Jose Polo Co-Founder | WordPressMySQLPHP+24 | Series A | 35 patents Cellular reprogramming and culture methods for regenerative therapies, e.g., cochlear hair cells | — |
| 6 | Laverock Therapeutics Developer of next generation of programmable cell therapies 24Funding top 29%Moat top 42%Talent bottom 49%Global bottom 45% All 6 signals ▾Fundingtop 29% Moattop 42% Talentbottom 49% Globalbottom 45% Techbottom 43% Marketbottom 27% Funding: Raised $39.3M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $39M | 12 mo ago | 6 | David Venables CEO | WebflowGSAPcore-js+13 | Seed | — | — |
| 7 | Nemaura Medical Provider of an AI-based blood-glucose monitoring system | $38M | 64 mo ago | 37 | — | WordPressPleskMySQL+20 | Public | — | — |
| 8 | Midatech Provider of novel drug delivery technologies for the treatment of diseases | $16M | 41 mo ago | 40 40 → 24 (-40%) | — | — | Public | 204 patents Patents concentrated in health & consumer products | 1 job opening · 1 expansion |
| 9 | PolyPhotonix Developer of photonic technology-based devices to treat diabetic retinotherapy | $10M | 53 mo ago | 8 | Richard Kirk CEO | — | Series A | 84 patents Phototherapy light devices for dermatological and wound healing treatments | 1 launch |
| 10 | Caldan Therapeutics UK-based, preclinical-stage biopharma developing therapeutics targeting free fatty acid receptors for Type 2… | $7M | 128 mo ago | 3 | Graeme Milligan Co-Founder & Director | — | Series A | — | — |
| 11 | Biodexa Pharmaceuticals Developer of therapeutics for the treatment of brain cancer | $7M | 30 mo ago | 26 | Stephen Stamp CEO | WordPressMySQLPHP+14 | Series A | — | — |
| 12 | Exonate Developer of small molecule drugs for retinal vascular diseases | $4M | 90 mo ago | 17 17 → 16 (-6%) | — | — | Seed | 54 patents Small-molecule kinase inhibitors and ocular anti‑angiogenic agents | — |
| 13 | Zihipp Developer of drugs for obesity and diabetes treatment | $4M | 77 mo ago | 5 | — | — | Series A | — | — |
| 14 | Caura App-based auto insurance platform for individuals | $4M | 41 mo ago | 10 | — | WebflowBootstrapAmazon Web Services+14 | Seed | 3 patents Secure vehicle control systems and encrypted automotive data communication | — |
| 15 | Accunostics Self monitoring devices for blood glucose analysis | $4M | 177 mo ago | 8 | Giles Hamilton CEO | — | Deadpooled | 13 patents Pulsed electrochemical analyte quantification in biological fluids for point‑of‑care diagnostics | — |
| 16 | Dia Beta Labs Developer of novel therapeutic peptides for metabolic disease treatment | $4M | 12 mo ago | — | Nigel Irwin Co-Founder | — | Seed | — | — |
| 17 | Biorasis Provider of a sensor platform for continuous glucose monitoring | $3M | 91 mo ago | 6 | — | — | Series A | — | — |
| 18 | Carbometrics Developer of glucose monitoring solution for diabetes | $3M | 26 mo ago | 13 | Anthony Davis Co-Founder & Director | — | Seed | 3 patents Carbohydrate detection sensors for analytical chemistry applications | — |
| 19 | PulseFlow Treatment for diabetic foot ulcers | $3M | 132 mo ago | 4 | — | — | Seed | — | — |
| 20 | Lein Applied Diagnostics Suite of measurement devices and solutions | $2M | 90 mo ago | 8 | — | — | Seed | 52 patents Optical measurement and alignment systems for medical diagnostic devices. | — |
| 21 | George Medicines Developer of single-pill combination treatments for cardiometabolic diseases | $2M | 47 mo ago | 2 | Mark Mallon CEO | WordPressMySQLPHP+19 | Seed | — | — |
| 22 | Quotient Diagnostics Develops Glycated haemoglobin (HbA1c) analysers to monitor the treatment of diabetes | $1M | 204 mo ago | 1 | Phillip Vessey Founder | — | Acquired | 16 patents Fluorescence-based whole blood diagnostic assays for clinical biomarker detection | — |
| 23 | Digostics Provider of home testing platforms for diabetes detection and management | $1M | 39 mo ago | 10 | Hugo Tewson Co-Founder | HubSpot CMS HubEnvoyGSAP+21 | Seed | — | 1 award |
| 24 | Luas Diagnostics Developer of sensors and connected app for diabetes management | $949K | 38 mo ago | 3 | — | — | Seed | — | — |
| 25 | Transdermal Diagnostics Provider of a needle-free continuous glucose monitoring device | $920K | 46 mo ago | 2 | Richard Guy Co-Founder | — | Seed | 5 patents Non‑invasive skin‑based biosensor platforms for measuring physiological analytes. | — |
| 26 | Afon Technology Provider of non-invasive blood glucose monitoring device 22Growth top 35%Funding top 48%Talent bottom 49%Global bottom 37% All 6 signals ▾Growthtop 35% Fundingtop 48% Talentbottom 49% Globalbottom 37% Techbottom 27% Marketbottom 22% Growth: Fresh capital in last 24 mo Funding: Raised $709k across 4 rounds · 4 rounds over 4 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $709K | 14 mo ago | 9 | Sabih Chaudhry CEO | WordPressMySQLPHP+17 | Seed | — | 1 launch |
| 27 | Thermology Health Developer of thermal imaging platform for early detection of foot ulcers | $191K | 12 mo ago | — | Yuval Yashiv Chief Executive Officer | — | Seed | — | — |
| 28 | Adelie Health Provider of device and app for managing insulin dosage | $107K | 88 mo ago | 1 | Liam Morrow Founder | — | Seed | — | — |
Top 12 Diabetes companies in United Kingdom
#1
Seed · Stevenage, England · founded 2021 · 6 employees$39.3Mraised▾
Developer of next generation of programmable cell therapies. The company utilizes gene editing induced gene silencing (GEiGS) technology, and its associated computational platform, to engineer induced pluripotent stem cell (iPSC) derived cell therapies.
- Jun 2025Seed$27.5M
- Sep 2023Seed$16.4M
- Aug 2022Seed$22.9M
#2
Seed · Belfast, Northern Ireland · founded 2022$3.5Mraised▾
Developer of novel therapeutic peptides for metabolic disease treatment. The company focused on developing novel therapeutic agents for metabolic diseases, particularly targeting the progressive decline of pancreatic beta-cell health in diabetes and obesity. They emphasize peptide analogues that are enzyme resistant, receptor selective, and highly soluble for better formulation. It aims for treatments that offer more sustainable, quality weight loss and better management of disease progression compared to current options.
- Jun 2025Seed$2M
- Jan 2025Grant (prize money)—
- Jan 2025Seed$1.5M
- Oct 2024Grant (prize money)$32.9K
#3
Series C · Cambridge, England · founded 2020 · 11 employees$371.5Mraised▾
Developer of therapeutic programs based on biological and medical research. The company's product pipeline include APL-9796: A first-in-class anti-ZIP12 monoclonal antibody for pulmonary hypertension, APL-045 and APL-10456, targeting neoplasms, immune disorders, and metabolic conditions via small molecules and antibodies.
- Sep 2023Series C$226.5M
- Jun 2021Series C$145M
#4
Seed · Chepstow, Wales · founded 2015 · 9 employees$709.2Kraised▾
Provider of non-invasive blood glucose monitoring device. The features of the patented device are high and low glucose warnings, continuous monitoring, personalized health trends, and others.
- May 2025Grant (prize money)$2.7M
- 2023Grant (prize money)$2.7M
- Feb 2023Grant (prize money)$2.6M
- Nov 2022Seed$709.2K
#5
Series A · Cambridge, England · founded 2016 · 51 employees$60.3Mraised▾
Developer of small molecule therapeutics for neurological disorders. It offers drugs that targets the fleeting protein intermediates, the oligomers to treat Parkinson’s disease, Alzheimer’s disease, and ALS.
- Apr 2024Series A$16M
- Feb 2021Series A$2.1M
- Dec 2020Series A$14.8M
- Oct 2018Series A$23.1M
#6
Series B · London, England · founded 2019 · 18 employees$344.2Mraised▾
Developer of engineered regulatory T cell therapies for immune diseases. This clinical-stage organization focuses on modifying a patient's own regulatory T cells to restore immune balance. These therapies aim to address conditions involving autoimmunity, chronic inflammation, and organ transplant rejection by dampening immune responses and preventing tissue damage. The approach utilizes cellular engineering to regulate immune activity and manage severe inflammatory disorders.
- Jan 2023Series B$24.1M
- Mar 2022Series B$57.9M
- Nov 2021Series B$156M
- Dec 2020Series A$34.9M
#7
Series A · Cambridge, England · founded 2014 · 45 employees$47.8Mraised▾
Developer of regenerative medicine and cell therapies. It is developing a technology platform to treat diseases in the fields of regenerative medicine and cell therapies. They have developed a proprietary tailored cellular conversion technology platform (systematic big-data approach). It enables gene-regulatory data to identify the combination of transcription factors (in vitro) or small molecules (in vivo).
- Oct 2023Series A$10M
- May 2021Series A$17M
- Jan 2020Series A$1.1M
- Oct 2019Series A$16M
#8
Seed · Teddington, England · founded 2023$190.9Kraised▾
Developer of thermal imaging platform for early detection of foot ulcers. The platform uses temperature data to aid clinicians in early identification. It creates medically accurate temperature data, backed by published clinical studies. The platform is suitable for use in both clinical and at-home settings.
- 2025Seed$190.9K
#9
Public · Abingdon, England · founded 2000 · 40 employees$16Mraised▾
Provider of novel drug delivery technologies for the treatment of diseases. It develops a pipeline of product candidates in clinical and pre-clinical development for diseases such as diabetes, rare cancers including brain, ovarian, liver, and pancreatic cancer, and neurological/ophthalmologic conditions. It provides in-house technology platforms for sustained release to prolong and control the release of therapeutics over an extended period of time and dissolve insoluble drugs which can be converted into liquid form and can be treated for tumor patients.
- Feb 2023Post IPO$6M
- Aug 2020Post IPO$1M
- 2020Grant (prize money)$56.1K
- Oct 2019Post IPO$3M
#10
Series A · Cardiff, Wales · founded 2000 · 26 employees$6.8Mraised▾
Developer of therapeutics for the treatment of brain cancer. It offers a lead candidate, MTX110 a solubilised formulation of the histone deacetylase inhibitor, panobinostat used in aggressive rare/orphan brain cancer indications which includes recurrent glioblastoma, medulloblastoma and paediatric diffuse midline glioma.
- Dec 2023Series A$6.8M
#11
Seed · Bristol, England · founded 2018 · 13 employees$2.6Mraised▾
Developer of glucose monitoring solution for diabetes. The platform has developed the proprietary molecule biomimetic glucose binding molecule, It is the glucose-sensing molecule that can monitor the glucose level in diabetes patient.
- May 2024Seed$2.6M
#12
Public · Loughborough, Scotland · founded 2011 · 37 employees$38Mraised▾
Provider of an AI-based blood-glucose monitoring system. Its features include a disposable patch, a watch, and a smartphone app. It integrates AI, monitoring, and digital platforms for the diagnosis and detection of chronic disease.
- Feb 2021Post IPO$24M
- Apr 2020Post IPO$6M
- Aug 2019Conventional Debt$8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diabetes coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.